GSK3B and Alzheimer disease: Furthermore, inhibition of GSK‐3β significantly alleviated Aβ‐induced excessive mitochondrial fission and type H blood vessel injury, indicating that GSK‐3β may be an important therapeutic target for bone loss in AD patients.